OKYO Pharma LtdNASDAQ:OKYO
- LAST PRICE1.4653
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 1.4653
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OKYO |
|---|---|---|
| 09:32 ET | 700 | 1.41 |
| 09:50 ET | 300 | 1.4523 |
| 09:56 ET | 400 | 1.42 |
| 09:57 ET | 6500 | 1.42 |
| 10:26 ET | 1100 | 1.4237 |
| 10:46 ET | 513 | 1.41 |
| 11:40 ET | 100 | 1.415 |
| 12:12 ET | 100 | 1.4001 |
| 12:20 ET | 100 | 1.41 |
| 12:38 ET | 674 | 1.41 |
| 01:03 ET | 712 | 1.4 |
| 01:15 ET | 100 | 1.4 |
| 03:07 ET | 510 | 1.4653 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
OKYO Pharma Ltd | 49.5M | -0.1x | --- |
Lantern Pharma Inc | 62.0M | -3.6x | --- |
RetinalGenix Technologies Inc | 62.2M | -29.1x | --- |
Mural Oncology PLC | 60.4M | -0.3x | --- |
Rallybio Corp | 63.1M | -1.0x | --- |
enVVeno Medical Corp | 63.7M | -2.4x | --- |
Company Information
OKYO Pharma Limited is a United Kingdom-based preclinical biopharmaceutical company. The Company is focused on developing an approach to dry eye care and ocular pain that is developing a lipidated chemerin-peptide drug candidate, OK-101, designed to target an ocular receptor controlling inflammation and ocular pain. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The Company operates through the research and development of biotechnological and pharmaceutical products segment. The Company’s technologies include Chemerin Receptor, OK-101 Drug Candidate and Preclinical Data. Its membrane anchored peptide (MAP) technology enabled the development of OK-101. Its drug candidate, OK-101, consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain. The Company’s wholly owned subsidiary is OKYO Pharma US Inc.
Contact Information
- Headquarters
- Floor 4, 14/15 Conduit StLONDON, United Kingdom W1S 2XJ
- Phone
- 207-495-2379
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $49.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 33.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-10.74 |
Book Value | $8.58 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
